{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:06:43Z","timestamp":1786118803056,"version":"build-2736575974"},"reference-count":28,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Sinovac Biotech Co., Ltd., Beijing, China"},{"name":"Sinovac Life Sciences Co., Ltd., China"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/21645515.2025.2579366","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:48:51Z","timestamp":1761824931000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Lot-to-lot consistency, immunogenicity, and safety of a 23-valent pneumococcal polysaccharide vaccine (PPV23) in healthy adults aged 40\u201365\u2009years: A randomized, double-blind, controlled, phase IV clinical trial"],"prefix":"10.1080","volume":"21","author":[{"given":"Yunong","family":"Zhang","sequence":"first","affiliation":[{"name":"Shanxi Provincial Center for Disease Control and Prevention","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Shi","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siliang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Sinovac Biotech","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shanxi Provincial Center for Disease Control and Prevention","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Sinovac Biotech","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jidong","family":"Li","sequence":"additional","affiliation":[{"name":"Yuanping First People\u2019s Hospital Medical Group","place":["Yuanping, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Yuanping First People\u2019s Hospital Medical Group","place":["Yuanping, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaimei","family":"Li","sequence":"additional","affiliation":[{"name":"Yanhu District Center for Disease Control and Prevention","place":["Yuncheng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxu","family":"Geng","sequence":"additional","affiliation":[{"name":"Sinovac Biotech","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuozhuo","family":"Chen","sequence":"additional","affiliation":[{"name":"Sinovac Biotech Co., Ltd","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Yuanping First People\u2019s Hospital Medical Group","place":["Yuanping, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[{"name":"Yanhu District Center for Disease Control and Prevention","place":["Yuncheng, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[{"name":"Sinovac Biotech Co., Ltd","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Jiao","sequence":"additional","affiliation":[{"name":"Sinovac Biotech Co., Ltd","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Li","sequence":"additional","affiliation":[{"name":"Shanxi Provincial Center for Disease Control and Prevention","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.2196\/50678"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61204-6"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00176-2"},{"key":"e_1_3_6_5_1","unstructured":"2020 China Health Yearbook. 2021 [accessed 2025 May 21]. http:\/\/www.nhc.gov.cn\/mohwsbwstjxxzx\/tjtjnj\/202112\/982dd4fa7f9f4b7f8ba9b752aa8aa2e3.shtml."},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100430"},{"issue":"12","key":"e_1_3_6_7_1","first-page":"1945","article-title":"Vaccine and immunology branch of the Chinese Preventive Medicine Association. Expert consensus on immunoprophylaxis of pneumococcal disease (2020 version)","volume":"41","author":"Chinese Preventive Medicine Association","year":"2020","unstructured":"Chinese Preventive Medicine Association. Vaccine and immunology branch of the Chinese Preventive Medicine Association. Expert consensus on immunoprophylaxis of pneumococcal disease (2020 version). Chin J Epidemiol. 2020;41(12):1945\u20131979.","journal-title":"Chin J Epidemiol"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1242419"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.11.003"},{"issue":"11","key":"e_1_3_6_10_1","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Nuorti JP","year":"2010","unstructured":"Nuorti JP, Whitney CG. Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep. 2010;59(RR\u201311):1\u201318.","journal-title":"MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep"},{"key":"e_1_3_6_11_1","unstructured":"Pneumococcal: The green book chapter 25. GOV.UK. 2023 Aug 14 [accessed 2025 May 14]. https:\/\/www.gov.uk\/government\/publications\/pneumococcal-the-green-book-chapter-25."},{"issue":"8","key":"e_1_3_6_12_1","first-page":"85","article-title":"Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper \u2013February 2019 \u2500 Vaccins antipneumococciques conjugu\u00e9s chez les nourrissons et les enfants de moins de 5 ans: note de synth\u00e8se de l\u2019OMS \u2013 f\u00e9vrier 2019","volume":"94","author":"Sant\u00e9 WHO= O mondiale de la","year":"2019","unstructured":"Sant\u00e9 WHO= O mondiale de la. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper \u2013February 2019 \u2500 Vaccins antipneumococciques conjugu\u00e9s chez les nourrissons et les enfants de moins de 5 ans: note de synth\u00e8se de l\u2019OMS \u2013 f\u00e9vrier 2019. Wkly Epidemiol Rec Relev\u00e9 \u00c9pid\u00e9miologique Hebd. 2019;94(8):85\u2013103.","journal-title":"Wkly Epidemiol Rec Relev\u00e9 \u00c9pid\u00e9miologique Hebd"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.04.093"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1509648"},{"key":"e_1_3_6_15_1","unstructured":"Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine (PPV23) in Chinese children adults and elderly: a phase 4 randomized double-blind active-controlled clinical trial | medRxiv. [accessed 2025 Apr 10]. https:\/\/www.medrxiv.org\/content\/10.1101\/2025.01.01.25319861v1."},{"key":"e_1_3_6_16_1","unstructured":"National Medical Products Administration. Technical guidelines for clinical comparability studies of preventive vaccines. 2019;94. https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20191224104601789.html. [In Chinese]."},{"key":"e_1_3_6_17_1","unstructured":"NMPA issued the guidelines for adverse event classification standards for clinical trials of preventive vaccines. [accessed 2025 Apr 10]. https:\/\/english.nmpa.gov.cn\/2019-12\/31\/c_448385.htm."},{"key":"e_1_3_6_18_1","unstructured":"Guidelines on clinical evaluation of vaccines: Regulatory expectations. [accessed 2025 Mar 13]. https:\/\/www.who.int\/publications\/m\/item\/WHO-TRS-1004-web-annex-9."},{"key":"e_1_3_6_19_1","unstructured":"Research C for BE and. Guidance for industry for the evaluation of combination vaccines for preventable diseases: production testing and clinical studies. 2024 Jul 26 [accessed 2025 Apr 10]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/guidance-industry-evaluation-combination-vaccines-preventable-diseases-production-testing-and."},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00588-7"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1342839"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1332472"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2040921"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13080866"},{"key":"e_1_3_6_25_1","unstructured":"Guidelines for adverse reaction classification standards for clinical trials of preventive vaccines. [accessed 2025 Sep 9]. https:\/\/www.nmpa.gov.cn\/xxgk\/fgwj\/gzwj\/gzwjyp\/20051014010101369_5.html?type=pc&m=."},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15030298"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.8476"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2517489"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060536"}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2025.2579366","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/21645515.2025.2579366","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2025.2579366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:48:56Z","timestamp":1786034936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2025.2579366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/21645515.2025.2579366"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2025.2579366","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2579366"}}